Literature DB >> 18159560

Probable linezolid-induced pancytopenia.

Nita Lakhani1, William Thompson, Anne Marie Bombassaro.   

Abstract

A 75-year-old male outpatient with cardiac disease, diabetes, chronic renal insufficiency and iron deficiency anemia was prescribed linezolid 600 mg twice daily for a methicillin-resistant Staphylococcus aureus diabetic foot osteomyelitis. After one week, his blood counts were consistent with baseline values. The patient failed to return for subsequent blood work. On day 26, he was admitted to hospital with acute renal failure secondary to dehydration, and was found to be pancytopenic (erythrocytes 2.5x10(12)/L, leukocytes 2.9x10(9)/L, platelets 59x10(9)/L, hemoglobin 71 g/L). The patient was transfused, and linezolid was discontinued. His blood counts improved over the week and remained at baseline two months later.The patient's decline in blood counts from baseline levels met previously established criteria for clinical significance. Application of the Naranjo scale indicated a probable relationship between pancytopenia and linezolid.Clinicians should be aware of this rare effect with linezolid, and prospectively identify patients at risk and emphasize weekly hematological monitoring.

Entities:  

Keywords:  Adverse reaction; Linezolid; Pancytopenia

Year:  2005        PMID: 18159560      PMCID: PMC2095045          DOI: 10.1155/2005/961613

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  14 in total

1.  Linezolid and reversible myelosuppression.

Authors:  S L Green; J C Maddox; E D Huttenbach
Journal:  JAMA       Date:  2001-03-14       Impact factor: 56.272

2.  Linezolid-induced pancytopenia.

Authors:  Michele Halpern
Journal:  Clin Infect Dis       Date:  2002-08-01       Impact factor: 9.079

3.  Challenges with linezolid therapy and reversible pancytopenia.

Authors:  H S Nimeiri; D S Nemiary
Journal:  Ann Hematol       Date:  2003-06-14       Impact factor: 3.673

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

6.  Pharmacokinetics of linezolid in subjects with renal dysfunction.

Authors:  Michael E Brier; Dennis J Stalker; George R Aronoff; Donald H Batts; Kristi K Ryan; Margaret O'Grady; Nancy K Hopkins; Gail L Jungbluth
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 7.  Linezolid: the first oxazolidinone antimicrobial.

Authors:  Robert C Moellering
Journal:  Ann Intern Med       Date:  2003-01-21       Impact factor: 25.391

8.  Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Authors:  Mary C Birmingham; Craig R Rayner; Alison K Meagher; Susan M Flavin; Donald H Batts; Jerome J Schentag
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

9.  Mechanisms for linezolid-induced anemia and thrombocytopenia.

Authors:  Wendy B Bernstein; Richard F Trotta; James T Rector; Jeffery A Tjaden; Anthony J Barile
Journal:  Ann Pharmacother       Date:  2003-04       Impact factor: 3.154

Review 10.  Chloramphenicol toxicity: 25 years of research.

Authors:  A A Yunis
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965

View more
  4 in total

1.  Comparison of Empiric Antibiotic Escalation Therapy with Vancomycin (VAN) versus Linezolid (LIN) in Patients with Febrile Neutropenia.

Authors:  Karin Mayer; Nicolaus Hegge; Ernst Molitor; Peter Brossart; Corinna Hahn-Ast
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

2.  Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Authors:  Daniel Wirth; Ramesh Dass; Robert Hettle
Journal:  BMC Health Serv Res       Date:  2017-03-08       Impact factor: 2.655

3.  Linezolid-Induced Pancytopenia in Patients Using Dapagliflozin: A Case Series.

Authors:  Meng Mei Li; Wen Cheng Shen; Yu Jin Li; Jun Teng
Journal:  Infect Drug Resist       Date:  2022-09-19       Impact factor: 4.177

4.  Reversible Myelosuppresion With Prolonged Usage of Linezolid in Treatment of Methicillin-Resistant Staphylococcus aureus.

Authors:  Sanjana Sharma; Arshi Syal; Monica Gupta; Anita Tahlan; Baldeep Kaur
Journal:  Cureus       Date:  2020-10-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.